Intervention

Talimogene Laherparepvec

ClinicalTrials.gov intervention label

Clinical trials4
Recruiting0
Common conditions25
Lead sponsors shown4
Advertisement

Clinical trials

4 shown
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerNCT03554044 · 2020-02-05
COMPLETED
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedNCT04185311 · 2019-07-10
TERMINATED
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesNCT03256344 · 2018-03-19
COMPLETED
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by SurgeryNCT02658812 · 2016-08-01
TERMINATED

Common conditions

Anatomic Stage IIIA Breast Cancer AJCC v82Anatomic Stage IIIB Breast Cancer AJCC v82HER2/Neu Negative2Prognostic Stage IIIA Breast Cancer AJCC v82Prognostic Stage IIIB Breast Cancer AJCC v82Recurrent Breast Carcinoma2Anatomic Stage 0 Breast Cancer AJCC v81Anatomic Stage I Breast Cancer AJCC v81Anatomic Stage IA Breast Cancer AJCC v81Anatomic Stage IB Breast Cancer AJCC v81Anatomic Stage II Breast Cancer AJCC v81Anatomic Stage IIA Breast Cancer AJCC v81Anatomic Stage IIB Breast Cancer AJCC v81Anatomic Stage III Breast Cancer AJCC v81Anatomic Stage IIIC Breast Cancer AJCC v81Anatomic Stage IV Breast Cancer AJCC v81Estrogen Receptor Positive1Invasive Breast Carcinoma1Invasive Ductal Carcinoma, Not Otherwise Specified1Malignant Chest Wall Neoplasm1Metastatic Colorectal Cancer1Metastatic Triple Negative Breast Cancer1Progesterone Receptor Negative1Prognostic Stage 0 Breast Cancer AJCC v81Prognostic Stage I Breast Cancer AJCC v81

Trial status mix

COMPLETED2
TERMINATED2

Phase mix

PHASE13
PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.